摘要
目的探讨缬沙坦治疗轻中度高血压的应用价值。方法选择医院2014年至2015年收治的120例轻中度高血压患者,按照随机数字表法分为研究组与对照组,每组60例。研究组口服缬沙坦治疗,对照组口服依那普利治疗,比较两组的临床疗效与不良反应发生情况。结果研究组治疗总有效率为96.67%,对照组为83.33%,差异有统计学意义(P<0.05)。治疗前,两组患者的收缩压(SBP)及舒张压(DBP)比较,差异无统计学意义(P>0.05);治疗4周末,研究组患者SBP及DBP明显低于对照组(P<0.05)。研究组不良反应发生率为3.33%,明显低于对照组的10.00%(P<0.05)。结论缬沙坦治疗轻中度高血压效果显著,可有效降低舒张压与收缩压,不良反应少,安全可靠,值得临床推广。
Objective To evaluate the efficacy and safety of valsartan in treating mild to moderate essential hypertension patients.Methods 120 cases of patients with mild to moderate hypertension from January 2014 to December 2015 in the hospital were randomly divided into the study group and the control group,60 cases in each group.The study group received valsartan treatment;the control group was treated with enalapril treatment.The clinical efficacy and adverse reactions of the two groups were compared.Results The total effective rate of the study group was 96.67%,the total effective rate of the control group was 83.33%,the difference was statistically significant（P〈0.05）.Before treatment,there was no significant difference in SBP and DBP between the two groups（P〈0.05）.The treatment of SBP and DBP in the study group was significantly lower than that in the control group at the end of 4 weeks（P〈0.05）.The incidence rate of adverse reactions in the study group was 3.33%,which was significantly lower than 10.00%of the control group（P〈0.05）.Conclusion Valsartan can reduce systolic and diastolic blood pressure significantly.It is well tolerated and has better safety,which is worthy of clinical promotion.
出处
《中国药业》
CAS
2016年第23期50-53,共4页
China Pharmaceuticals
关键词
缬沙坦
依那普利
轻中度高血压
临床疗效
valsartan
enalapril
mild to moderate hypertension
clinical efficacy
